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t(8;21)(q22;q22) is present in ∼5–10% of patients with de novo acute myeloid leukemia
(AML) and is associated with a better overall prognosis. Variants of the t(8;21) have been
described in the literature, however, their clinical and prognostic significance has not been
well-characterized. Molecular profiling of these cases has not previously been reported
but may be useful in better defining the prognosis of this subset of patients. We present
two cases of variant t(8;21) AML including clinical, cytogenetic, and molecular data.
Keywords: acute myeloid leukemia, t(8;21), cytogenetics, core binding factor, variant
BACKGROUND
Acute myeloid leukemia (AML) with t(8;21)(q22;q22) is known as a core binding factor AML.
Along with inv(16)(p13;q22)/t(16;16)(p13;q22), this cytogenetic abnormality has been shown to
have a more favorable prognosis, especially when treated with high dose cytarabine based therapy
(1–3). The t(8;21) is found in ∼5–10% of de novo AML and results in the creation of the fusion
gene RUNX1-RUNX1T1 (1, 4–6). In most affected individuals, the chromosomal breakpoints are
located at intron 5 of the RUNX1 gene and intron 1 of the RUNX1T1 resulting in an in-frame fusion
of the N-terminal 177 amino acids of RUNX1 with almost the entire RUNX1T1 protein (7). The
RUNT domain from RUNX1, the four nervy homology regions (NHR), and a nuclear localization
signal (NLS) from RUNX1T1 are major functional domains of the fusion protein (8, 9). By direct
or indirect binding to target DNA regions, the RUNX1-RUNX1T1 regulates the expression of
various groups of genes involved in multiple signaling pathways. It has been shown that the
RUNX1-RUNX1T1 alone is not sufficient for leukemogenic transformation, and the number of
mutations necessary for the development of AML1-ETO leukemia is still unknown (5, 6, 10).
Variant translocations account for∼3–4% of leukemias with RUNX1/RUNX1T1 fusion transcripts,
some of which are cytogenetically cryptic and can only be identified by molecular approaches (e.g.,
quantitative PCR). Clinical consequences of these variants are poorly defined (11–15). Here, we
present two similar cases of variant t(8;21) identified at our institution, their molecular findings on
next generation sequencing, and their clinical outcomes.
MATERIALS AND METHODS
Conventional Cytogenetic Analysis
The bone marrow specimens were cultured in MarrowMAX medium (Invitrogen, Carlsbad, CA)
for 24 and 48 h, respectively. Metaphase chromosomes for Giemsa banding pattern by trypsin
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digestion with Wright stain (GTW banding) were prepared
according to standard procedures. Twenty metaphases were
karyotyped with GenASIs BandView Analysis System (Applied
Spectral Imaging, Carlsbad, CA), and karyograms were described
according to the International System for Human Cytogenetic
Nomenclature 2016.
Fluorescent in-situ Hybridization (FISH)
Assay
FISH analysis on monolayer interphase nuclei and metaphases
harvested from bone marrow cultures was undertaken using
commercially available FISH probes in the AML panel (Vysis,
Abbott Park, IL). Standard FISH hybridization and washing
protocols were followed. The slides were then counterstained
with the 4′,6-diamidino-2-phenylindole (DAPI). Hybridization
signals were captured and analyzed with a GenASIs FISHView
Analysis System (Applied Spectral Imaging, Carlsbad, CA). At
least 200 cells were scored for each probe set.
Molecular Pathology Studies
Hematological Malignancy Gene Panel Mutation Analysis, a
comprehensive targeted next generation sequencing (NGS) assay,
FLT3 internal tandem duplication (ITD) mutation analysis,
and JAK2 V617F Mutation Analysis were performed in the
Molecular and Genomic Pathology Laboratory of Thomas
Jefferson University Hospital. In brief, the NGS panel was
designed in-house to detect somatic mutations in 48 genes that
are recurrently mutated in myeloid malignancies. Input DNA is
processed using the Illumina TruSight(TM) Myeloid Sequencing
Panel and sequenced on an Illumina MiSeq sequencer. The
assay has sufficient sensitivity to detect mutations present in
a heterozygous state at a 5% allele frequency. FLT3 internal
tandem duplication (ITD) mutation analysis was performed by
amplifying a 329 base-pair fragment of the FLT3 gene including
the ITD insertion sites and is sufficient to detect an ITD of
1% allele frequency. The JAK2 V617F mutation analysis was
performed using an allelic discrimination assay according to the




A 62-year-old female with a history of hypertension and
adenocarcinoma of the breast treated with radiation and
tamoxifen was referred to our hospital for an abnormal complete
blood count (CBC). On admission, her white blood cell
(WBC) count was 5 × 103/µL with 17% blasts, hemoglobin
was 9.1 g/dL, and platelet count was 22 × 103/µL. Bone
marrow biopsy revealed a prominent population of blasts
with round to irregular, intermediate sized nuclei, prominent
nucleoli, and scant to moderate cytoplasm, comprising 59%
by manual count. Several blasts contained dark azurophilic
and large salmon colored cytoplasmic granules. Auer rods
were not apparent. Concomitant flow cytometry of the bone
marrow detected an increased myeloblast population showing
the following antigenic profile: CD10–, CD13–, CD14–, CD16–,
TABLE 1 | Clinicopathologic findings in two patients with variant t(8;21).
Characteristics Patient #1 Patient #2
Age/Sex 62/F 63/F
Diagnosis Acute myeloid leukemia Acute myeloid leukemia
Hemoglobin 9.1 g/dL 9.1 g/dL
Platelet 22,000 B/L 4,000 B/L
WBC 5.0 B/L 6.1 B/L
PB blasts, % 17 67
BM blasts,% 59 75
Cellularity,% 50 60
Morphology Blasts with round to irregular,
intermediate sized nuclei,
prominent nucleoli, and scant
to moderate cytoplasm;
several blasts contained dark
azurophilic and large salmon
colored cytoplasmic granules;
no Auer rods
Medium sized blasts with fine
nuclear chromatin, small
nucleoli, and scant cytoplasm;
no cytoplasmic granules or
Auer rods






CD4+ (dim, partial), CD13–
(partial, dim), CD14–, CD33+,
CD34+, CD38+ (partial, dim),
CD56, CD61 (dim), CD64–,
CD117+, and HLA DR+
(dim).
CD19+ (aberrant), CD33+(dim), CD34+(bright), CD38+,
CD56–, CD64–, CD117+, HLA-DR+(bright) (Table 1). This was
consistent with a diagnosis of AML.
Conventional Cytogenetics and FISH
Conventional cytogenetics study revealed an apparently
reciprocal translocation between the long arms of chromosomes
8 and 21 at 8q22 and 21q22 [t(8;21)] in twenty of twenty
metaphases analyzed. However, FISH on interphase nuclei
showed an atypical pattern with one fusion signal representing
either der(8) or der(21) (indistinguishable on interphase nuclei)
resulting from a typical translocation, two green signals (2G)
representing either an intact or partial RUNX1 (AML1) gene at
21q22, and a single red signal (1R) representing either an intact
or partial RUNX1T1 (ETO) gene at 8q22. FISH on metaphases
showed a derivative chromosome 8 carrying a fusion signal of
RUNX1T1 and RUNX1, a derivative chromosome 21 carrying
the green colored RUNX1 (AML1) signal alone consistent with
an absence of the RUNX1T1 (ETO) signal and indicative of a
sub-microscopic deletion following the t(8;21) (the green signal
in fact represented the 3′ RUNX1 gene), a copy of a normal
chromosome 8 (red), and a copy of a normal chromosome





RUNX1x3)(RUNX1 con RUNX1T1x1)[165/200], (RPN1,
MECOM,EGR1,DEK,D7S522,ASS1,ABL1,CAN,KMT2A,PML,
CBFB,RARA,TP53,BCR)x2[200].
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FIGURE 1 | Abnormal cytogenetic and FISH findings in Patient #1. (A) Representative karyogram of an apparent t(8;21)(q22;q22) observed in 11 of 20 metaphases
analyzed, unable to show submicroscopic small deletions due to cytogenetic technic limitation. The aberration was re-written as
der(8)t(8;21)(q22;q22),der(21)del(8)(q22q22)t(8;21) based on FISH findings in (B,C). Arrows indicate aberrant chromosomes. Chromosome numbers are listed on the
bottom. (B) Interphase FISH study using dual color dual fusion probes demonstrating an atypical pattern with one fusion signal for RUNX1-RUNXT1, one signal (red)
for the RUINX1T1 locus, and two signals (green) for the RUNX1T1 locus. (C) Metaphase FISH study using dual color dual fusion probes demonstrating a derivative
chromosome 8 [der(8)] carrying a fusion signal of RUNX1T1 and RUNX1, a derivative chromosome 21 [der(21)] carrying the green colored RUNX1 signal alone
consistent with a sub-microscopic deletion of the rearranged 8q22 segment encompassing the 5′ RUNX1T1, a copy of a normal chromosome 8 [N(8)] and a copy of a
normal chromosome 21 [N(21)].
TABLE 2 | Hematologic malignancy gene panel findings in two patients with variant t(8;21).
Patient #1 Patient #2
Gene ASXL1 DNMT3A IDH1 RAD21
Genomic position (hg19) chr20:31023092 chr2:25469128 chr2:209113113 chr8:117866547
Nucleotide change c.2578delA (NM_015338.5) c.1328_1329dupCT (NM_175629.2) c.394C>T (NM_005896.2) c.1097delC (NM_006265.2)
Amino acid change p.R860Efs*7 p.E444Lfs*208 p.R132C p.T366Kfs*4
Cosmic ID None 4678897:4678898 COSM28747 None
Altered allele frequency 44.80% 43.60% 41.30% 41.20%
Classification Pathogenic Pathogenic Pathogenic Pathogenic
Molecular Pathology Assays
A pathogenic mutation in the gene RAD21 was identified
(Table 2) and the study of internal tandem duplications (ITDs)
in the FLT3 gene was negative.
RAD21 encodes a subunit of the cohesin complex, which
controls the separation of sister chromatids during mitosis and
functions in other processes including transcription and DNA
repair. Mutations associated with myeloid malignancies are
found throughout the gene and cause inactivation of the protein
(16). About 3% of AML and 1–2% ofMDS cases are found to have
mutations in the RAD21 gene (17, 18). A higher frequency of
cohesin defects has been observed in secondary AML and high-
risk MDS patients, and cohesin defects have been associated with
poor overall survival in MDS patients (16).
Outcome
The patient underwent induction with conventional idarubicin
and cytarabine. This was complicated only by neutropenic fever
without an identified infectious source. A complete cytogenetic
remission (CR) was achieved. Molecular profiling was not
repeated at the time of her remission bone marrow biopsy.
She proceeded immediately to four cycles of consolidation with
high-dose cytarabine, which were completed without delays or
major complications. She has remained in CR for 18 months.
Patient #2
Clinicopathologic Findings
A 63-year-old female with a history significantly only for a
renal mass treated with partial nephrectomy was transferred to
our hospital with fatigue, bone pain, and an abnormal CBC.
She was found to have a WBC count of 6.1 × 103/µL with
67% blasts, hemoglobin of 9.1 g/dL, and platelets 4 × 103/µL.
Bone marrow biopsy showed an increase in number of blasts
(75% by manual count). The blasts were medium in size, had
fine nuclear chromatin, small nucleoli, and scant cytoplasm. No
cytoplasmic granules or Auer rods were seen. Bone marrow
flow cytometry detected myeloblasts (69%) with the following
antigenic pattern: CD4+ (dim, partial), CD13– (partial, dim),
CD14–, CD33+, CD34+, CD38+ (partial, dim), CD56–, CD61–,
CD64–, CD117+, and HLA-DR+ (dim) (Table 1). A diagnosis of
AML was made.
Conventional Cytogenetics and FISH
Similar to Patient #1, conventional cytogenetics revealed an
apparently reciprocal translocation between the long arms
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of chromosomes 8 and 21 at 8q22 and 21q22 [t(8;21)] in
twenty of twenty metaphases analyzed. However, FISH on
interphase nuclei showed two atypical signal patterns for
the RUNX1/RUNX1T1 translocation probe set: the first was
consistent with the presence of a derivative chromosome
(one fusion signal) presumably arising from a reciprocal
t(8;21) translocation along with one copy of RUNX1T1 (1R)
and two copies of RUNX1 (2G), and the second showed
two copies of RUNX1T1 (2R) and three copies of RUNX1
(3G). While metaphase FISH analysis later proved that the
derivative chromosome represented a der(8), whether the
extra RUNX1 signal resulted from a trisomy 21 or from
sequential structural alterations following a t(8;21) was unable
to be determined. In addition, a low level TP53 deletion was






FIGURE 2 | Abnormal cytogenetic and FISH findings in Patient #2. (A) Representative karyogram of an apparent t(8;21)(q22;q22) observed in all of 20 metaphases
analyzed, unable to show submicroscopic small deletions due to cytogenetic technic limitation. The aberration was re-written as
der(8)t(8;21)(q22;q22),der(21)t(8;21)del(8)(q22q22) based on FISH findings in (B,C). Arrows indicate aberrant chromosomes. Chromosome numbers are listed on the
bottom. (B) Interphase FISH study using dual color dual fusion probes demonstrating an atypical pattern with one fusion signal for RUNX1-RUNXT1, one signal (red)
for the RUINX1T1 locus, and two signals (green) for the RUNX1T1 locus. (C) Metaphase FISH study using dual color dual fusion probes demonstrating a derivative
chromosome 8 [der(8)] carrying a fusion signal of RUNX1T1 and RUNX1, a derivative chromosome 21 [der(21)] carrying the green colored RUNX1 signal alone
consistent with a sub-microscopic deletion of the rearranged 8q22 segment encompassing the 5′ RUNX1T1, a copy of a normal chromosome 8 [N(8)] and a copy of a
normal chromosome 21 [N(21)]. (D) Interphase FISH study using dual color dual fusion probes demonstrating a second atypical pattern with two signals (red) for the
RUINX1T1 locus, three signals (green) for the RUNX1T1 locus and no fusion signal for RUNX1-RUNXT1.
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Molecular Pathology Assays
Pathogenic mutations were found in three genes: ASXL1,
DNMT3A, and IDH1 (Table 2). The studies of JAK2 V617F
mutation and internal tandem duplications (ITDs) in the FLT3
gene were both negative.
ASXL1 encodes a chromatin-binding Polycomb group (PcG)
protein involved in transcriptional regulation (19). Somatic
mutations in ASXL1 have been reported in 10.8% adults with
de novo AML, and in 17.2% of AML cases with intermediate
risk cytogenetics (20, 21). DNMT3A encodes DNA (cytosine-5)-
methyltransferase 3A and is essential for establishing genome-
wide patterns of CpG methylation during development. It is also
important for regulating gene expression, parental imprinting,
and maintaining genome integrity (22). The Cancer Genome
Atlas Research Network identified mutations in the DNMT3A
gene in 51/200 (26%) de novo AML samples (17). Isocitrate
dehydrogenases, which include IDH1 and IDH2, catalyze the
oxidative decarboxylation of isocitrate to 2-oxoglutarate (alpha-
ketoglutarate) (23, 24). Approximately 6–9% of AML cases are
found to have mutations in the IDH1 gene, with a higher
frequency in normal karyotype-AML (8–16%) (19). Studies of
the prognostic significance of ASXL1, DNMT3A, and IDH
mutations in AML have reported complex and sometimes
conflicting results, although most reports support negative
effects on prognosis (19–21). The co-occurrence of mutations in
epigenetic regulators, including ASXL1, DNMT3A, and IDH1,
has also been reported (25–27). However, the frequency and
clinical consequences of this combination of mutations in core
binding factor AML are not well-characterized.
Outcome
The patient underwent treatment with conventional idarubicin
and cytarabine induction. This was complicated by neutropenic
fever without an identified infectious source and the development
of a rash that was thought to be due to cytarabine. A
cytogenetic CR was achieved. Molecular profiling was not
repeated at the time of her remission bone marrow biopsy.
She proceeded immediately to consolidation with high dose
cytarabine. Unfortunately, she completed 3 cycles and then her
disease relapsed. Cytogenetics at the time of relapse showed
the same t(8;21), and molecular profiling identified the same
mutations in ASXL1, DNMT3A, and IDH1 that were present
at diagnosis. She underwent re-induction on a clinical trial,
however, her disease was refractory. She subsequently began
treatment with an IDH1 inhibitor and her disease was stable for
∼4 months. At the time of disease progression, she opted for
hospice. The patient died 14 months after her diagnosis.
DISCUSSION
Although AML with t(8;21)(q22;q22) is generally is associated
with a favorable prognosis, it is unclear if the same can be
said for variant t(8;21) (1–3, 11). Our patients had similar
variant subtypes of t(8;21) and were treated with idarubicin
and cytarabine induction therapy. Both achieved a complete
remission, however, Patient #1 has remained in CR after
consolidation chemotherapy, while Patient #2 relapsed and
subsequently died.
Published outcomes for other variant cases are similarly
heterogeneous. Kawakami et al. (13) described a case of a 37-
year-oldmanwith a variant t(8;21) that demonstrated a three way
translocation between chromosomes 8,9, and 21. This patient
had an AML1/ETO fusion transcript that was identical to the
fusion transcript found in patients with classic t(8;21), however,
he did not achieve a complete remission with idarubicin and
cytarabine (13). Similarly, a 15-year-old patient with a four
way translocation t(8;17;15;21)(q22;q23;q15;q22) was reported,
and he also showed rapid progression of his disease (28). An
additional variant form of t(8;21) was reported in a 10-year-old
female with a translocation between chromosomes 4, 8, and 21,
with loss of the X chromosome and a gain of chromosome 6. She
had an early relapse and a poor outcome (29).
Another paper reported three cases of variant t(8;21) AML.
Two patients had three way translocations; the first with a
translocation between chromosomes 8, 18, and 21 as well as a
del(7)(q32q34) and the second with a translocation involving
chromosomes 2, 8, and 21 with loss of the Y chromosome. The
third patient had a derivative eight with the interstitial inverted
insertion of 21q and concurrent monosomy 21; this patient
achieved CR for 15 months before relapse (11). Another author
presented four patients with variant forms of t(8;21). Two of
these patients had three-way translocations, one with t(1;8;21)
and the other with t(8;11;21), and a third patient had a four way
translocation between chromosomes 4, 8, 12, and 21. The fourth
patient reported had three neoplastic clones in which the segment
of chromosome 8 containing bands q22 through q24.1 had been
duplicated and inverted (the t(8;21) had been inserted within
the duplicated segment. All four of these patients achieved a CR
(30). Another patient described in the literature with a complex
translocation involving chromosomes 1, 8, and 21 with del 9q22
and loss of the X chromosome had no reported outcome (31).
Although the prognosis for patients with variant t(8;21) is
generally unclear, certain markers have been associated with
outcomes. For example, loss of the sex chromosome and del (9q)
have been associated with shorter overall survival, and trisomy
4 has been thought to be associated with a poorer prognosis
(11, 13). AML1/ETO frequently expresses positivity for CD19
and CD56 and, although CD19 positivity is not thought to alter
prognosis, it has been reported that CD56 is associated with
shorter remission time and survival. Additionally, c-kit and EML
are thought to be associated with a negative outcome (13).
The cytogenetic abnormalities that occur from
t(8;21)(q22;q22) result in the disruption of a transcription
factor that functions as a regulator of hematopoiesis. In patients
with classical t(8;21) AML, remission rates after induction
chemotherapy with an anthracycline and cytarabine approaches
90% (10). Although these responses are considered favorable, the
median survival for these patients, according to long term follow
up reports, is 5 years or less (2). Variant t(8;21) is much less
common than traditional CBF AML, and it has been reported
that the majority of patients with variant rearrangements have a
complex translocation involving a third chromosome (28). The
reported responses to therapy for these patients are varied.
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Little is known about the molecular landscape of patients
with variant t(8;21). Previously reported cases did not include
molecular data, likely because many were published prior to the
routine use of NGS in AML diagnosis. However, extrapolation
from the body of literature regarding molecular mutations in
classical t(8;21) AML may be possible. In general, tyrosine kinase
mutations such as KIT and FLT3 are most common in this
subset of patients and co-mutations in these genes can be seen
(32–34). Mutations in KIT have been clearly shown to correlate
with shortened remission duration and decreased overall survival
in t(8;21) AML (35, 36). The prognostic significance of KIT
mutations in inv(16) AML is less clearly defined (37, 38).
Mutations in epigenetic regulators and members of the cohesin
complex, including ASXL1, IDH1/2, and RAD21, have also been
identified in a significant subset of t(8;21) AML. Interestingly,
these mutations are vanishingly rare in inv(16) AML (32).
Whether the genetic profile of variant t(8;21) is similar to that of
classical t(8;21) remains to be determined, however, the patients
presented here do share similar molecular signatures to those
described in CBF AML.
We provide the first description of two cases of variant
t(8;21) along with their molecular profiles. Additional reports
of similar cases are needed in order to better determine the
interplay between, and the clinical significance of, the cytogenetic
and molecular abnormalities. The two patients presented in this
paper with variant t(8;21) both achieved complete remission
with standard induction therapy, however, only one had a
durable response.
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